Literature DB >> 8438136

[Indications for chemoprophylaxis of tuberculosis. Arguments for].

L P Nicod1.   

Abstract

After a first infection with M. tuberculosis, reactivation of the disease may be prevented by chemoprophylaxis with isoniazid or rifampicin. Such chemoprophylaxis should be administered to all subjects with an immune defect due to HIV infection, immunosuppressors, severe diabetes, renal insufficiency or silicosis. Extensive sequelae of tuberculosis on chest X-ray are also a major risk of reactivation without treatment. Tuberculosis is most likely to become active during the first three years following first infection for an healthy subject. However, beyond this limit or when the time of infection is unknown, the most objective decisional analysis still demonstrates the clear-cut benefit of chemoprophylaxis in proportion to its side effects for all young subjects aged less than 35 years.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8438136

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  3 in total

1.  Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes.

Authors:  L Tentori; G Graziani; S A Porcelli; M Sugita; M B Brenner; R Madaio; E Bonmassar; A Giuliani; A Aquino
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

2.  Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis.

Authors:  Rama Yerramasetti; Sastry Gollapudi; Sudhir Gupta
Journal:  J Clin Immunol       Date:  2002-01       Impact factor: 8.317

3.  Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs.

Authors:  Sastry Gollapudi; Suman Jaidka; Sudhir Gupta
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.